Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.

Proc Natl Acad Sci U S A 2012 Sep 15;109(37):E2476-85. Epub 2012 Aug 15.

Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA 94305, USA.

Up-regulation of the folding machinery of the heat-shock protein 90 (Hsp90) chaperone protein is crucial for cancer progression. The two Hsp90 isoforms (α and β) play different roles in response to chemotherapy. To identify isoform-selective inhibitors of Hsp90(α/β)/cochaperone p23 interactions, we developed a dual-luciferase (Renilla and Firefly) reporter system for high-throughput screening (HTS) and monitoring the efficacy of Hsp90 inhibitors in cell culture and live mice. HTS of a 30,176 small-molecule chemical library in cell culture identified a compound, N-(5-methylisoxazol-3-yl)-2-[4-(thiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-ylthio]acetamide (CP9), that binds to Hsp90(α/β) and displays characteristics of Hsp90 inhibitors, i.e., degradation of Hsp90 client proteins and inhibition of cell proliferation, glucose metabolism, and thymidine kinase activity, in multiple cancer cell lines. The efficacy of CP9 in disrupting Hsp90(α/β)/p23 interactions and cell proliferation in tumor xenografts was evaluated by non-invasive, repetitive Renilla luciferase and Firefly luciferase imaging, respectively. At 38 h posttreatment (80 mg/kg × 3, i.p.), CP9 led to selective disruption of Hsp90α/p23 as compared with Hsp90β/p23 interactions. Small-animal PET/CT in the same cohort of mice showed that CP9 treatment (43 h) led to a 40% decrease in (18)F-fluorodeoxyglucose uptake in tumors relative to carrier control-treated mice. However, CP9 did not lead to significant degradation of Hsp90 client proteins in tumors. We performed a structural activity relationship study with 62 analogs of CP9 and identified A17 as the lead compound that outperformed CP9 in inhibiting Hsp90(α/β)/p23 interactions in cell culture. Our efforts demonstrated the power of coupling of HTS with multimodality molecular imaging and led to identification of Hsp90 inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1205459109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443147PMC
September 2012
21 Reads

Publication Analysis

Top Keywords

cell culture
12
hsp90 inhibitors
12
molecular imaging
8
hsp90α/β/p23 interactions
8
cell proliferation
8
mice cp9
8
degradation hsp90
8
interactions cell
8
multimodality molecular
8
client proteins
8
hsp90 client
8
heat-shock protein
8
hsp90
7
cp9
7
cell
6
inhibitors
5
cp9 binds
4
n-5-methylisoxazol-3-yl-2-[4-thiophen-2-yl-6-trifluoromethylpyrimidin-2-ylthio]acetamide cp9
4
binds hsp90α/β
4
cp9 treatment
4

References

(Supplied by CrossRef)

Zhang et al.
Journal of molecular medicine (Berlin, Germany) 2004

Neckers et al.
Current opinion in oncology 2003

Yano et al.
Cancer letters 1999

Myung et al.
2004

Le Brazidec et al.
Journal of medicinal chemistry 2004

Chiosis et al.
Current topics in medicinal chemistry 2006

Kamal et al.
Nature; Physical Science (London) 2003

Vetcher et al.
Applied and Environmental Microbiology 2005

Vilenchik et al.
Chemistry & biology 2004

Moulick et al.
Bioorganic & Medicinal Chemistry Letters 2006

Llauger et al.
Journal of medicinal chemistry 2005

Similar Publications